The DOI matches its Crossref record; 86 of the 88 references it cites were found in a registry or an index.
Isocitrate Dehydrogenase 1 and 2 Mutations in Cancer: Alterations at a Crossroads of Cellular Metabolism
Open accessAbstract
Dysregulation of metabolism is a common phenomenon in cancer cells. The NADP(+)-dependent isocitrate dehydrogenases 1 and 2 (IDH1 and IDH2) function at a crossroads of cellular metabolism in lipid synthesis, cellular defense against oxidative stress, oxidative respiration, and oxygen-sensing signal transduction. We review the normal functions of the encoded enzymes, frequent mutations of IDH1 and IDH2 recently found in human cancers, and possible roles for the mutated enzymes in human disease. IDH1 and IDH2 mutations occur frequently in some types of World Health Organization grades 2-4 gliomas and in acute myeloid leukemias with normal karyotype. IDH1 and IDH2 mutations are remarkably specific to codons that encode conserved functionally important arginines in the active site of each enzyme. To date, all IDH1 mutations have been identified at the Arg132 codon. Mutations in IDH2 have been identified at the Arg140 codon, as well as at Arg172, which is aligned with IDH1 Arg132. IDH1 and IDH2 mutations are usually heterozygous in cancer, and they appear to confer a neomorphic enzyme activity for the enzymes to catalyze the production of D-2-hydroxyglutarate. Study of alterations in these metabolic enzymes may provide insights into the metabolism of cancer cells and uncover novel avenues for development of anticancer therapeutics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“There is a renewed interest in the area of cancer metabolism with metabolic reprogramming coined as a hallmark of cancer based on the discovery of mutations and alterations in IDH1 and IDH2 along with succinate dehydrogenase (SDH), fumarate hydratase (FH), and pyruvate kinase M2 (PKM2) [41, 42].”
From Modeling APC mutagenesis and familial adenomatous polyposis using human iPS cells (2018) · cites this paper as [42]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
UCSF Chimera—A visualization system for exploratory research and analysis
Pettersen, E. F., Goddard, T. D., Huang, C. C., Couch, G. S., Greenblatt, D. M., Meng, E. C., & Ferrin, T. E. (2004) · Journal of Computational Chemistry · doi:10.1002/jcc.20084 · Cited by 45,882
The 2007 WHO Classification of Tumours of the Central Nervous System
Louis, D. N., Ohgaki, H., Wiestler, O. D., Cavenee, W. K., Burger, P. C., Jouvet, A., Scheithauer, B. W., & Kleihues, P. (2007) · Acta Neuropathologica · doi:10.1007/s00401-007-0243-4 · Cited by 15,656
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857
Self-citationIDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
Self-citationCancer-associated IDH1 mutations produce 2-hydroxyglutarate
Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., Fantin, V. R., Jang, H. G., Jin, S., Keenan, M. C., et al. (2009) · Nature · doi:10.1038/nature08617 · Cited by 4,154
The Consensus Coding Sequences of Human Breast and Colorectal Cancers
Sjöblom, T., Jones, S., Wood, L. D., Parsons, D. W., Lin, J., Barber, T. D., Mandelker, D. L., Leary, R. J., Ptak, J., Silliman, N., et al. (2006) · Science · doi:10.1126/science.1133427 · Cited by 3,161
Recurring mutations found by sequencing an acute myeloid leukemia genome
Mardis, E. R., Ding, L., Dooling, D. J., Larson, D. E., McLellan, M. D., Chen, K., Koboldt, D. C., Fulton, R. S., Delehaunty, K. D., McGrath, S. D., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0903840 · Cited by 2,219
Ward, P. S., Patel, J., Wise, D. R., Abdel-Wahab, O., Bennett, B. D., Coller, H. A., Cross, J. R., Fantin, V. R., Hedvat, C. V., Perl, A. E., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.01.020 · Cited by 2,020
Hartmann, C. J., Meyer, J., Balß, J., Capper, D., Mueller, W. C., Christians, A., Felsberg, J., Wolter, M., Mawrin, C., Wick, W., et al. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0561-9 · Cited by 1,163
Glioma-Derived Mutations in IDH1 Dominantly Inhibit IDH1 Catalytic Activity and Induce HIF-1α
Zhao, S., Lin, Y., Xu, W., Jiang, W., Zha, Z., Wang, P., Yu, W., Li, Z., Gong, L., Peng, Y., et al. (2009) · Science · doi:10.1126/science.1170944 · Cited by 1,119
Research works printed but not linked: 7
- 2008, 154, 1107
- 2004, 86, 501
- 2001, 83, 1057
- 2008, 90, 1316
- 2009, Cancer Science, 15, 6002
- 2009, Human mutation, 31, 279
- 2009, New England Journal of Medicine, 360, 2248, 10.1056/NEJMc090593 · DOI
Cited by
Sorted by citations
Items 401–500 of 567
Algahtani, H. A., Shirah, B. H., Tashkandi, M., & Samkari, A. M. N. (2020) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2020.101945 · Cited by 4
Heiblig, M., Khalife‐Hachem, S., Willekens, C., Micol, J., Paci, A., Penard‐Lacronique, V., & de Botton, S. (2020) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2020.1831909 · Cited by 4
Aging of the sensory systems: hearing and vision disorders
Someya, S., & Ikeda, A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-815962-0.00014-7 · Cited by 4
Glioblastoma: a molecular genetic portrait and modern therapeutic strategies for drug treatment
Guens, G. P., Sanikovich, V. D., Mileyko, V., & Lebedeva, A. (2021) · Advances in molecular oncology · doi:10.17650/2313-805x-2021-8-3-60-76 · Cited by 4
“Основная роль IDH состоит в возобновлении запаса НАДФ-Н, который участвует во многих реакциях в клетке, в том числе в получении энергии из жиров и защите от реактивных форм кислорода [59].”
Zhou, X., Zheng, M., Zhao, N., Hu, Y., Yang, K., Huo, J., Liu, G., Huang, J., Chen, L., Zhou, Y., et al. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.105569 · Cited by 4
NAD+ as a Target for Cancer Treatment
Helman, T. J., & Braidy, N. (2023) · Springer eBooks · doi:10.1007/978-3-030-80962-1_269-1 · Cited by 4
Bello, R. O., Okunola, S. T., Kumar, N., Omoboyede, V., Jimoh, T. O., Abdulsalam, Z. N., Kehinde, I. O., & Umar, H. I. (2023) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2023.2245494 · Cited by 4
“While IDH1 and 2 are located in the cyto-plasm and mitochondria, respectively, IDH3 is located in the mitochondrial matrix (Reitman & Yan, 2010) Mutations in IDH1 and IDH2 occur at preserved arginine residues within the enzymatic active site, precisely at the R132 locus of IDH1 and the R140 or…”
Pappert, F. A., Wüst, V. A., Eguiguren, C. F., & Roth, O. (2025) · Molecular Ecology · doi:10.1111/mec.17754 · Cited by 3
Physiology and Pathology of Mitochondrial Dehydrogenases
Romani, A. (2018) · InTech eBooks · doi:10.5772/intechopen.76403 · Cited by 4
“Similarly, defects in isocitrate dehydrogenase [24], a-ketoglutarate dehydrogenase [25] succinate dehydrogenase [26], and pyruvate dehydrogenase [27] have all been reported in a variety of cancer cells, and associated with the metabolic reprogramming these cells undergo.”
BackgroundInhibition of Cancer Metabolism: a Patent Landscape
Katt, W. P., & Cerione, R. A. (2019) · Pharmaceutical Patent Analyst · doi:10.4155/ppa-2019-0012 · Cited by 4
Classification of Primary Brain Tumors: Molecular Aspects
Molnár, P. (2011) · InTech eBooks · doi:10.5772/22484 · Cited by 4
Genetic Markers in Adult High-Grade Gliomas
Pekmezci, M., & Perry, A. (2014) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2014.06.005 · Cited by 4
Peric, D., Labarre, J., Chevalier, F., & Rousselet, G. (2012) · PROTEOMICS · doi:10.1002/pmic.201100461 · Cited by 4
“thioredoxin-dependent peroxidases PRDX1 and PRDX3 [19], and the biliverdin reductase BLVRB [20]), one by reducing NADP+ to NADPH (the NADP-dependent isocitrate dehydrogenase IDH1 [21]), and one as a molecular chaperone (the heat shock protein HSP27 [22]).”
BackgroundMapping seizure foci and tumor genetic factors in glioma associated seizure patients
Yunhe, M., Yang, Y., Wang, X., Yanhui, L., & Mao, Q. (2020) · Journal of Neurosurgical Sciences · doi:10.23736/s0390-5616.17.04015-2 · Cited by 4
State of the Art of IDH Inhibitors: Emerging Questions and Perspectives
de Lima, J. A. L., & Lima, L. M. (2025) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/0118715206382095250908095950 · Cited by 3
Advancements in targeted therapies for acute myeloid leukemia
Connor, M. P., Barsouk, A. A., Elghawy, O., & Lai, C. (2025) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2025.102604 · Cited by 4
Zhao, Y., Ou, C., Huang, H., Wang, Y., Shen, J., Li, Y., He, Q., Han, Z., Xie, Y., Zhong, T., et al. (2026) · Cancer Research · doi:10.1158/0008-5472.can-25-2313 · Cited by 3
Yumashev, A. V., Shuxrat, B., Khayotbek, K., Кодиров, У. А., Elmurodova, A., Rufat, A., Urinova, N., & Abduraxmonova, I. (2026) · Clinical & Translational Oncology · doi:10.1007/s12094-026-04334-4 · Cited by 3
“1) [21].”
Singh, S., Jain, K., Singh, J., Garg, N., & Arora, A. (2024) · Indian Journal of Medical and Paediatric Oncology · doi:10.1055/s-0044-1779621 · Cited by 3
Targeting IDH1 mutation-driven Nrf2 signaling to suppress malignant behavior in fibrosarcoma cells
Park, S., Chun, K., & Kim, D. (2025) · Toxicological Research · doi:10.1007/s43188-025-00284-1 · Cited by 3
Genetic Mutations in Acute Myeloid Leukemia
Blau, O. (2016) · Clinical oncohematology · doi:10.21320/2500-2139-2016-9-3-245-256 · Cited by 3
“Функция обоих генов находится в центре процессов клеточного метаболизма, дыхания клетки, клеточной защиты от окислительного стресса и передачи сигналов [128].”
Novel Drugs Targeting the Epigenome
Chen, Z., & Li, H. (2017) · Current Pharmacology Reports · doi:10.1007/s40495-017-0100-7 · Cited by 3
“IDH1 and IDH2 enzymes catalyze the NADP-dependent oxidative decarboxylation of isocitrate to α-ketoglutarate (α-KG) [86].”
Alves, J., Dexheimer, G. M., Reckzigel, L., Goettert, M. I., Biolchi, V., & Abujamra, A. L. (2019) · Journal of Hematology · doi:10.14740/jh531 · Cited by 3
“IDH2 plays a role in energy production and a crucial role in cellular proliferation [37].”
BackgroundNovel canine isocitrate dehydrogenase 1 mutation Y208C attenuates dimerization ability
Kawakami, S., Michishita, M., Sakaue, M., Morimatsu, M., Uemura, M., Kashiwagi, N., Maeda, M., Machida, Y., Azakami, D., Egusa, A. S., et al. (2020) · Oncology Letters · doi:10.3892/ol.2020.12214 · Cited by 3
“Further analysis of the IDH1 gene structure confirmed these findings, identifying IDH1 mutations in over 70% of secondary GBM or low‑grade gliomas, but infrequently in primary GBM (5,6).”
BackgroundJafari, S. H., Rabiei, N., Taghizadieh, M., Mirazimi, S. M. A., Kowsari, H., Farzin, M. A., Bahabadi, Z. R., Rezaei, S., Mohammadi, A. H., Alirezaei, Z., et al. (2021) · Pathology - Research and Practice · doi:10.1016/j.prp.2021.153528 · Cited by 3
Bali, H., Yu, J., Beale, P. J., & Huq, F. (2020) · Journal of Angiotherapy · doi:10.25163/angiotherapy.41210611810120920 · Cited by 3
“However, controversy still exists regarding the role of IDHC in cancer, whether it provides oncogenic effects or tumour suppressive effects (Reitman and Yan 2010).”
BackgroundCertain aspects of radiomics and radiogenomics in glioblastoma: what the images hide?
Евгеньевич, М. Н., Труфанов, Г. Е., & Efimtsev, A. Y. (2022) · Translational Medicine · doi:10.18705/2311-4495-2022-9-2-70-80 · Cited by 3
Guerini, C., Furlan, D., Ferrario, G., Grillo, F., Libera, L., Arpa, G., Klersy, C., Lenti, M. V., Riboni, R., Solcia, E., et al. (2023) · Histopathology · doi:10.1111/his.15095 · Cited by 3
Cologni, R., Holschbach, M. H., Schneider, D., Bier, D. D., Schulze, A., Stegmayr, C., Endepols, H., Ermert, J., Neumaier, F., & Neumaier, B. (2024) · Molecules · doi:10.3390/molecules29163939 · Cited by 3
“Members of the isocitrate dehydrogenase (IDH) family are key metabolic enzymes that catalyze the oxidative decarboxylation of isocitrate to α -ketoglutarate ( α -KG) in the cytosol and peroxisomes (IDH1) or mitochondria (IDH2 and IDH3) of all eukaryotic cells [1].”
BackgroundIvosidenib for the treatment of relapsed or refractory acute myeloid leukemia with an IDH1 mutation
Pasquier, F., Chahine, C., Marzac, C., & de Botton, S. (2020) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2020.1792286 · Cited by 3
Parallel evolution of IDH2 gene in cetaceans, primates and bats
Ai, W., Chen, S., Chen, X., Shen, X., & Shen, Y. (2013) · FEBS Letters · doi:10.1016/j.febslet.2013.12.005 · Cited by 3
Nikitin, P. V., Aa, P., Ryzhova, M. V., Shurkhay, V. A., Kulikov, E. E., Zhvansky, E. S., Popov, I. A., & Николаев, Е. Н. (2018) · Burdenko s Journal of Neurosurgery · doi:10.17116/neiro2018823112 · Cited by 3
5-Methylcytosine and 5-Hydroxymethylcytosine Signatures Underlying Pediatric Cancers
Jhanwar, S., & Deogade, A. (2019) · Epigenomes · doi:10.3390/epigenomes3020009 · Cited by 3
“Moreover, aberrations in cofactor biochemical pathways involving 2-oxoglutarate, together with mutations in IDH1/2 [23], SDH, and FH [24] may alter levels of 5hmC and 5mC in certain types of tumors, in either a direct or indirect manner [25].”
BackgroundSmall cell glioblastoma: A glioblastoma subtype with an unexpected response
Bizu, I., Géorgescu, M., & Anghel, R. M. (2019) · Medicina Moderna - Modern Medicine · doi:10.31689/rmm.2019.26.2.93 · Cited by 3
Glioblastoma: Multidisciplinary treatment approaches
Sánchez, L. M. (2016) · Applied Radiation Oncology · doi:10.37549/aro1090 · Cited by 3
Liang, X., Tan, S., Chen, Y., Wei, C., & Qin, Z. (2025) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2025.578570 · Cited by 2
Iqbal, B., Saeed, M. T., Naz, T., Mohamed, H., Dang, W., Ramadan, A. S., Eltoukhy, A., Zhang, H., & Song, Y. (2025) · Applied Biochemistry and Biotechnology · doi:10.1007/s12010-025-05318-w · Cited by 2
“They are involved in lipid synthesis, oxidative respiration, cellular defense against oxidative stress, and oxygen-sensing signal transmission [53].”
Scaffold modification and synthesis routes for targeting mutant IDH 1: a review
Pai, V. S., & Kumar, N. (2025) · Discover Applied Sciences · doi:10.1007/s42452-025-07293-7 · Cited by 2
“IDH1 and IDH2 operate as NADP ⁺ - dependent homodimers, utilizing divalent metal ions such as Mg 2 ⁺ or Mn 2 ⁺ for their catalytic function [4].”
Li, M., Chen, J., Bao, W., Ma, S., Wen, M., Han, Y., Zhang, W., Yang, Y., Guo, X., & Li, B. (2025) · Cells · doi:10.3390/cells14161265 · Cited by 2
“IDH2 encodes a mitochondrial enzyme that plays a key role in the tricarboxylic acid cycle by catalyzing the oxidative decarboxylation of isocitrate to produce α -ketoglutarate and NADPH [8].”
Watany, M. M., & Elhosary, M. M. (2025) · The Journal of Applied Laboratory Medicine · doi:10.1093/jalm/jfaf124 · Cited by 2
Miteva‐Staleva, J., Krumova, E. T., & Angelova, M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26199308 · Cited by 2
“The role of ICDH in the strategy against oxidative stress has been demonstrated in a range of organisms, including Pseudomonas fluorescens [75], Drosophila [76], rat liver cells [77], and cancer cells [78].”
HOT mutation screening in human glioblastomas
Krell, D., Mulholland, P. J., Stebbing, J., Tomlinson, I. P. M., & Bardella, C. (2015) · Future Science OA · doi:10.4155/fso.15.20 · Cited by 2
Chung, C. (2021) · Annals of Pharmacotherapy · doi:10.1177/10600280211036154 · Cited by 2
Himed, S., Chung, C. G., Jones, D. M., Wall, S. A., & Kaffenberger, B. H. (2022) · International Journal of Dermatology · doi:10.1111/ijd.16089 · Cited by 2
Current trends in Glioblastoma
Koçak, M., Atasoy, Ö., Çini, N., & Erbaş, O. (2021) · Demiroglu Science University Florence Nightingale Journal of Medicine · doi:10.5606/fng.btd.2021.25074 · Cited by 2
“[11] 12-14] IDH3 is a heterotetrameric complex enzyme that catalyzes the conversion of isocitrate to alpha-ketoglutarate ( a -KG) in the tricarboxylic acid cycle in a nicotinamide adenine dinucleotide (NAD+) dependent manner.”
BackgroundKittur, P. M., Satheesan, L., Tanuj, G. N., Somagond, Y. M., Madhusoodan, A. P., Gandham, R. K., Alex, R., & Dang, A. K. (2025) · Scientific Reports · doi:10.1038/s41598-025-08433-0 · Cited by 2
“IDH1 catalyzes the oxidative decarboxylation of isocitrate to alpha-ketoglutarate, producing NADPH, essential for mammary FA synthesis 31 .”
Mapping carbon utilization pathways in Histoplasma capsulatum through 13 C-metabolic flux analysis
Heckart, A., Cocuron, J., Ray, S. C., Matheny, G. F., Rappleye, C. A., & Alonso, A. P. (2025) · mSystems · doi:10.1128/msystems.00569-25 · Cited by 2
“However, isocitrate dehydrogenase (Vidh) was maintained as bidirectional due to increasing evidence of its reversibility in various organisms (34, 35, 42, 43).”
Yu, L., & Qi, S. (2011) · Oncology Letters · doi:10.3892/ol.2011.447 · Cited by 2
“In contrast to the affirmatively prognostic value of IDH1 mutation in gliomas (4,26), the prognostic value of TET2 mutations in myeloid malignancies remains unclear (27).”
Ghashghaeinia, M., Wieder, T., & Duszenko, M. (2014) · CRC Press eBooks · doi:10.1201/b16653-22 · Cited by 2
Владимирович, И. Е., Савченко, А. А., Слепов, Е. В., & Khlebopros, R. G. (2014) · Siberian medical review · doi:10.20333/25000136-2014-1-25-29 · Cited by 2
“Однако при снижении интенсивности субстратного потока и недостатке водорода в митохондриях, НАДФИЦДГ может включаться в ЦТК в качестве вспомогательного фермента, катализирующего образование a-кетоглутарата [13].”
Владимирович, И. Е., & Савченко, А. А. (2017) · Doklady Biochemistry and Biophysics · doi:10.1134/s1607672917040081 · Cited by 2
Fernández-Calero, T., López, I., Davyt, M., Chalar, C., Ehrlich, R., & MAR蚇, M. (2022) · Biocell · doi:10.32604/biocell.2022.020966 · Cited by 1
Rocha, A. D. J. M., Alves, P. G. J. M., & de Souza, E. B. (2023) · Revista Brasileira de Cancerologia · doi:10.32635/2176-9745.rbc.2023v69n3.3970 · Cited by 1
The development of a hiPSC-based platform to identify tissue-dependencies of IDH1 R132H
Mehjardi, N., Keßler, J., Sanin, A. Y., Picard, D. J., Westhoff, P., Nickel, A., Uhlmann, C., Shi, W., Steiger, H., Remke, M., et al. (2023) · Cell Death Discovery · doi:10.1038/s41420-023-01747-w · Cited by 1
“…of isocitrate to α -ketoglutarate ( α -KG) and CO2, and converts NAD(P) + into NAD(P)H. Single nucleotide mutations in IDH exons are a frequent molecular parameter in a variety of cancers [1], with mutations in the R-encoding codon 132 of IDH1 representing the most frequently found alteration [2].”
BackgroundSaelue, P., Sinthujaroen, P., Suwiwat, S., & Thongsuksai, P. (2024) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/10760296241263099 · Cited by 1
Hasbay, B., Kayaselçuk, F., Süner, H. İ., & Tufan, K. (2025) · Vojnosanitetski pregled · doi:10.2298/vsp241008042h · Cited by 1
Biswal, A. S., Nandeshwar, N., Tripathy, U., & Chatterjee, S. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.148571 · Cited by 1
Wyckoff, C., Osgood, C. J., Jing, E., & Stacey, M. W. (2026) · Onco · doi:10.3390/onco6010016 · Cited by 1
“This hypothesis is informed by the convergence of data on D2HG’s ability to inhibit α -KG-dependent dioxygenases and the demonstrated capacity of mitochondria to retain and shuttle such metabolites into recipient cells [15,16].”
Josephine, A., Kumar, S. A., Varalakshmi, S., & Rajendran, P. (2026) · 3 Biotech · doi:10.1007/s13205-026-04753-8 · Cited by 1
Noh, S., Park, E. J., Choi, J., Lee, S., Jang, S. J., & Kim, S. H. (2011) · Basic and Applied Pathology · doi:10.1111/j.1755-9294.2011.01105.x · Cited by 1
Targeting Mutant IDH to Treat Low-grade Glioma
Peters, K. B. (2023) · touchREVIEWS in Oncology & Haematology · doi:10.17925/ohr.2023.19.2.3 · Cited by 1
Alzahrani, M. F. (2024) · Journal of Applied Hematology · doi:10.4103/joah.joah_97_24 · Cited by 1
Weir, M. C. (2016) · D-Scholarship@Pitt (University of Pittsburgh) · Cited by 1
Molecular Genetic Testing for Acute Myeloid Leukemia
Janečková, V., Semerád, L., Ježíšková, I., Dvořáková, D., Čulen, M., Šustková, Z., Mayer, J., & Ráčil, Z. (2016) · Klinicka onkologie · doi:10.14735/amko2016411 · Cited by 1
The changing molecular landscape of AML and its impact on treatment
Finn, L. E., Davis, C. T., Lunski, M., Khan, M. A., Staton, A. D., & Badari, A. R. (2020) · Integrative Molecular Medicine · doi:10.15761/imm.1000405 · Cited by 1
“Instead, IDH mutations generate 2-hydroxyl glutarate (2-HG), an ‘onco-metabolite’ which interferes with cellular regulatory mechanisms, ultimately halting cell differentiation and promoting leukemic tumor genesis [25-27].”
BackgroundAdvances in New Targets for Differentiation Therapy of Acute Myeloid Leukemia
Yao, J., Zhao, M., Wang, J., & Wei, L. (2020) · Journal of cancer research updates · doi:10.30683/1929-2279.2020.09.10 · Cited by 1
MicroRNA Regulation of Glycolytic Metabolism in Glioblastoma
Alfardus, H., McIntyre, A., & Smith, S. J. (2020) · Vide Leaf, Hyderabad eBooks · doi:10.37247/pabs.1.2020.7 · Cited by 1
Evaluating the anti-leukemia activity of avocatin B
Lee, E. A. (2015) · UWSpace (University of Waterloo) · Cited by 1
MaREA: Metabolic feature extraction, enrichment and visualization of RNAseq dataPreprint
Graudenzi, A., Maspero, D., Isella, C., Filippo, M. D., Mauri, G., Médico, E., Antoniotti, M., & Damiani, C. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/248724 · Cited by 1
“In particular, up regulation of NADPH-dependent isocitrate dehydrogenase, which catalyzes the reductive carboxylation of -ketoglutarate (AKG) to isocitrate, may be linked with the mutations often reported for this enzyme in breast and other cancer types [30].”
BackgroundNovel treatments of glioblastoma in experimental models
Förnvik, K. (2020) · Lund University Publications (Lund University) · Cited by 1
Ji, X., Sun, W., Lv, C., Huang, J., & Zhang, H. (2022) · Research Square · doi:10.21203/rs.3.rs-1493404/v1 · Cited by 1
IDH1 (Isocitrate Dehydrogenase 1)
Bristot, I. J., França, F. S., & Klamt, F. (2017) · Springer eBooks · doi:10.1007/978-3-319-67199-4_101639 · Cited by 1
Discovery and application of colorectal cancer protein markers for disease stratification
Zhou, J. (2013) · The Sydney eScholarship Repository (The University of Sydney)
Bianco, A. D. M. (2013) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2013.tde-01112013-122908
Biomarker Discovery, Validation and Clinical Application for Patients Diagnosed with Glioma
Kerrie, L. (2011) · InTech eBooks · doi:10.5772/21765
Paul, S. (2015) · Universitätsbibliothek der FU Berlin Hochschulschriftenstelle u. Dokumentenserver · doi:10.17169/refubium-14296
Terapie molecolari mirate e antiangiogeniche nel trattamento dei glioblastomi
Ducray, F., & Idbaïh, A. (2012) · EMC - Neurologia · doi:10.1016/s1634-7072(12)62645-2
Znaczenie mutacji genów modulujących zmiany epigenetyczne w ostrej białaczce szpikowej
Zajac, M., & Giannopoulos, K. (2013) · Acta Haematologica Polonica · doi:10.1016/j.achaem.2013.11.001
“procesach metabolizmu komórkowego, takich jak synteza lipidów oraz obrona przed stresem oksydacyjnym [11].”
BackgroundWalton, A. H. (2013) · University of the Witwatersrand, Johannesburg Institutional Repository on DSpace (University of the Witwatersrand, Johannesburg)
Malignant Glioma: Isocitrate Dehydrogenases 1 and 2 Mutations
Reitman, Z. J., & Yan, H. (2011) · Springer eBooks · doi:10.1007/978-94-007-0618-7_7
“Percentages were reported by Yan et al. (2009), except for OA and AOA which were reported by Hartmann et al. (2009 )s ince relatively few OA and AOA tumors were analyzed in Yan et al. Figure reproduced from Reitman and Yan (2010) with permission and adapted to include percentages”
Self-citationOtto Warburg's contributions to current concepts of cancer metabolism
Butenandt, A. (2011)
Hydrodynamic delivery for prevention of acute kidney injury
Zhang, S. (2015) · IUScholarWorks (Indiana University) · doi:10.7912/c2/2174
Identification of idh1 mutation-related gene signature of glioblastoma multiforme
Zhou, Z. (2014) · Tampere University Institutional Repository (Tampere University)
Thérapies moléculaires ciblées et antiangiogéniques dans le traitement des glioblastomes
Ducray, F., & Idbaïh, A. (2012) · Encyclopédie médico-chirurgicale. Neurologie · doi:10.1016/s0246-0378(12)56535-8
Malenda, A., & Nowis, D. (2013) · Via Medica Journals
Bruchelt, G., Handgretinger, R., Weckenmann, M., & Hahn, T. (2014) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-1-4614-9545-1_5
“In some tumor cells, additional possibilities to enhance NADPH for a more effective regeneration of GSH from GSSG include expression of IDH1 which converts isocitrate to α-ketoglutarate [104] (Fig.”
BackgroundОСОБЕННОСТИ МЕТАБОЛИЗМА АССОЦИИРОВАННЫХ С ОПУХОЛЬЮ МАКРОФАГОВ У МЫШЕЙ С АСЦИТНОЙ КАРЦИНОМОЙ ЭРЛИХА
Владимирович, И. Е., & Савченко, А. (2017) · Доклады Академии наук · doi:10.7868/s086956521721023x
Metabolic Dysregulation in Environmental Carcinogenesis and Toxicology
Robey, R. B. (2017) · John Wiley & Sons, Inc. eBooks · doi:10.1002/9781119023647.ch15
Functional alteration of canine isocitrate dehydrogenase 2 (IDH2) via an R174K mutation
Kawakami, S., Ochiai, K., Kato, Y., Michishita, M., Hirama, H., Obara, R., Azakami, D., Watanabe, M., & Omi, T. (2017) · Journal of Veterinary Medical Science · doi:10.1292/jvms.17-0362
“In the human study, IDH mutants (usually R132H of IDH1 and R172K of IDH2) lead to lower cellular α-KG levels, which may lead to inactivation of prolyl hydroxylases [3, 16].”
BackgroundZaburzenia mechanizmów epigenetycznych w ostrej białaczce szpikowej
Wiśniewski, K., Białopiotrowicz, E., & Góra‐Tybor, J. (2018) · Hematologia · doi:10.5603/hem.2018.0012
Molecularly Targeted Therapy for Patients with BRAF Wild-Type Melanoma
Chandra, S., McArthur, G., & Sosman, J. (2019) · Cutaneous Melanoma · doi:10.1007/978-3-319-46029-1_55-1
Urban-Sosa, V. A., Olvera-Sánchez, S., Barrera, D., Aragón-Hernández, J. P., Flores-Herrera, Ó., & Martínez, F. (2019) · Placenta · doi:10.1016/j.placenta.2019.09.008
Tischer, A., Antelo, G. B., Coltro, G., Finke, C. M., Gonsalves, W. I., Pardanani, A. D., Ketterling, R. P., Mangaonkar, A. A., Gangat, N., Tefferi, A., et al. (2019) · Leukemia Research · doi:10.1016/j.leukres.2019.106264
Metadata of the chapter that will be visualized in SpringerLink
Fass, D. (2017) · Zhytomyr State University Library (Zhytomyr Ivan Franko State University)
Hsu, P., Chen, C., Wei, K., Chen, C., & Chen, L. Y. (2020) · Interdisciplinary Neurosurgery · doi:10.1016/j.inat.2020.100922
Management of Relapsed/Refractory Acute Myeloid Leukemia
Jammal, N., Chew, S., Ravandi, F., Kantarjian, H. M., & Jabbour, E. J. (2020) · Hematologic malignancies · doi:10.1007/978-3-030-53633-6_6
Genetic and Molecular Aspects of the Aging Auditory System
Someya, S., & Kim, M. (2020) · Springer handbook of auditory research · doi:10.1007/978-3-030-49367-7_2
Metadata
- Authors
- Reitman, Z. J., & Yan, H.
- Affiliations
- Duke University (US)
- Venue
- JNCI Journal of the National Cancer Institute
- Publisher
- Oxford University Press (OUP)
- Published
- 2010-05-31
- Volume
- 102
- Issue
- 13
- Pages
- 932-941
- ISSN
- 0027-8874 (ISSN-L)
- 1460-2105
- PMC
- PMC2897878
- OpenAlex
- W2124951199
- Cited by
- 562
- References
- 88
- Citations by year
- 2026: 22 · 2025: 41 · 2024: 20 · 2023: 33 · 2022: 31 · 2021: 44 · 2020: 40 · 2019: 43 · 2018: 40 · 2017: 36 · 2016: 31 · 2015: 34 · 2014: 28 · 2013: 34 · 2012: 38
- FWCI
- 3.18
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- JNCI Journal of the National Cancer Institute (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- Funders
- National Cancer Institute (R01CA118822, R01CA140316)
- National Institute of General Medical Sciences (T32GM007171)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Biochemical Acid Research Studies
- Keywords
- IDH1, IDH2, IDH1 mutation, IDH2 mutation, cancer metabolism, glioma, acute myeloid leukemia, D-2-hydroxyglutarate, oxidative stress, lipogenesis, oxygen sensing, anticancer agents
- MeSH terms
- Animals, Hypoxia, Arginine, Brain Neoplasms, Codon, Glioblastoma, Glucose, Glutarates, Humans, Isocitrate Dehydrogenase, Mutation, NADP, Neoplasms, Oligodendroglioma, Oncogenes, Signal Transduction, Up-Regulation, Gene Expression Regulation, Enzymologic, Gene Expression Regulation, Neoplastic, Genes, Tumor Suppressor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
